Search
Belantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawn[L53673] Later that year in October of 2025, belantamab was granded full approval by the FDA for the a similar indication to the Health Canada one. [L54331] … Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).
Categories: P-glycoprotein substratesPiperacillin
go.drugbank.com/drugs/DB00319ApprovedInvestigationalSemisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.
Mixtures: AUROTAZ-P 4.5 G, Aurotaz-P Powder for Injections 4.5 gProducts: Pipracil-pws IV Im 2g/vial, Pipracil-pws IV Im 3g/vialSpirapril
go.drugbank.com/drugs/DB01348ApprovedInvestigationalSpirapril is an ACE inhibitor antihypertensive drug used to treat hypertension. Spirapril is converted to the active spiraprilat after administration.
PT-2385
go.drugbank.com/drugs/DB16055InvestigationalPT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).
Vorapaxar
go.drugbank.com/drugs/DB09030ApprovedVorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history … By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesFenofibric acid
go.drugbank.com/drugs/DB13873ApprovedInvestigationalFenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. … [A32038,L12855] Due to its high hydrophilicity and poor absorption profile,[A32038] prodrug ,[fenofibrate], and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have been developed
Methyldopa
go.drugbank.com/drugs/DB00968ApprovedInvestigationalMethyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. … [A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects.
Dinoprost tromethamine
go.drugbank.com/drugs/DB01160ApprovedVet approvedWithdrawnThe tromethamine (THAM) salt of the naturally occurring prostaglandin F2 alpha, dinoprost tromethamine occurs as a white to off-white, very hygroscopic, crystalline powder. … Dinoprost tromethamine may also be known as dinoprost trometamol, PGF2 alpha THAM, or prostaglandin F2 alpha tromethamine.
Lumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigationalimprovement of at least 5%. … [A20301] When used in combination with [DB08820] as the fixed dose combination product Orkambi, lumacaftor is specific for the management of CF in patients with delta-F508 mutations as it acts as a protein-folding
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inducersRaloxifene
go.drugbank.com/drugs/DB00481ApprovedInvestigationalIn addition, a clinical study consisting of postmenopausal women with documented coronary heart disease or at increased risk for coronary events showed an increased risk for fatal stroke with raloxifene … [label] It is strongly advised that the risk-benefit ratio is considered before starting raloxifene therapy in women at risk of thromboembolic disease or strokes, such as the prior history of stroke, transient
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 Inhibitors